EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY-NC-ND 4.0

Diagnostic Utility of Plasma Cytokeratin-18 (M30) in Detecting Nonalcoholic Fatty Liver Disease Among Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Study

V. Ashwini, C. K. Vijayasamundeeswari, Jeevankumar Murali, V. Manikandan, Rangasamy Sudha, Panneerselvam Periasamy

Journal of Pharmacy and Bioallied Sciences · 2026-10 · 18 (4) · 335-337

DOI: 10.4103/jpbs.jpbs_244_26 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift Journal of Pharmacy and Bioallied Sciences, online erschienen am 17.11.2026. Verfasst von V. Ashwini und 5 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A BSTRACT Background: Nonalcoholic fatty liver disease (NAFLD) is a common hepatic complication of type 2 diabetes mellitus (T2DM) and often remains undiagnosed until advanced stages. Plasma cytokeratin-18 (CK-18 M30), a marker of hepatocyte apoptosis, has emerged as a potential noninvasive biomarker for NAFLD.

Aim

To evaluate the diagnostic utility of plasma CK-18 (M30) for detecting ultrasound-defined NAFLD in patients with T2DM and compare its performance with the Fatty Liver Index (FLI) and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI). Materials and Methods: This hospital-based analytical cross-sectional study included 88 adults with T2DM, comprising 44 patients with ultrasonography-confirmed NAFLD and 44 without NAFLD. Clinical, anthropometric, and biochemical parameters, including plasma CK-18 M30, were assessed. FLI and APRI were calculated using standard formulas. Receiver operating characteristic (ROC) analysis and multivariable logistic regression were performed.

Results

Patients with NAFLD had significantly higher body mass index, waist circumference, HbA1c, triglycerides, liver enzymes, C-reactive protein, and plasma CK-18 M30 levels than those without NAFLD (all P < 0.05). CK-18 M30 demonstrated good diagnostic accuracy (AUC = 0.828; 95% CI: 0.732–0.924) with an optimal cutoff >86 U/L, sensitivity of 79.5%, and specificity of 72.7%. Its performance was comparable with APRI (AUC = 0.816) and FLI (AUC = 0.789). Body mass index, CK-18 M30, HbA1c, and gamma-glutamyl transferase were independent predictors of NAFLD.

Conclusion

Plasma CK-18 (M30) is a reliable noninvasive biomarker for detecting NAFLD in patients with T2DM and may improve early risk stratification in routine clinical practice.

Zitieren

APA

Ashwini, V., Vijayasamundeeswari, C. K., Murali, J., Manikandan, V., Sudha, R., & Periasamy, P. (2026). Diagnostic Utility of Plasma Cytokeratin-18 (M30) in Detecting Nonalcoholic Fatty Liver Disease Among Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Study. Journal of Pharmacy and Bioallied Sciences, 18(4), 335-337. https://doi.org/10.4103/jpbs.jpbs_244_26

Vancouver

Ashwini V, Vijayasamundeeswari CK, Murali J, Manikandan V, Sudha R, Periasamy P. Diagnostic Utility of Plasma Cytokeratin-18 (M30) in Detecting Nonalcoholic Fatty Liver Disease Among Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Study. Journal of Pharmacy and Bioallied Sciences. 2026;18(4):335-337. doi:10.4103/jpbs.jpbs_244_26

BibTeX
@article{Ashwini2026,
  author = {Ashwini, V. and Vijayasamundeeswari, C. K. and Murali, Jeevankumar and Manikandan, V. and Sudha, Rangasamy and Periasamy, Panneerselvam},
  title = {Diagnostic Utility of Plasma Cytokeratin-18 (M30) in Detecting Nonalcoholic Fatty Liver Disease Among Patients with Type 2 Diabetes Mellitus: A Hospital-Based Cross-Sectional Study},
  journal = {Journal of Pharmacy and Bioallied Sciences},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {335--337},
  doi = {10.4103/jpbs.jpbs_244_26}
}
Kostenlos starten →